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Introduction
Celiac disease is a well-known small bowel enteropathy resulting in
intestinal inflammation and atrophy in the setting of genetically predisposed
gluten sensitivity. After ingestion, gluten is broken down along the small
bowel brush border most notably resulting in gliadin. Gliadin is then broken
down by tissue transglutaminase (tTG) resulting in deaminated gliadin.
About 1% of the general population has developed antibodies to various
enzymes and products along this pathway resulting in clinical manifestations
of celiac disease [1,4]. Celiac disease most often presents in childhood with
nonspecific symptoms including vomiting, diarrhea, abdominal pain and
distension; though malabsorption may be severe enough to cause
malnutrition and failure to thrive.
Due to its protean manifestations, celiac serology is often requested for
chronic non-febrile ailments for which there is no obvious cause. Though
small bowel biopsy remains the gold standard for confirmatory diagnosis,
initial screening for antibodies targeted at enzymes and products along the
gluten metabolism pathway in symptomatic patients that continue gluten
consumption is recommended. The American Gastroenterology Association
identifies anti-tissue transglutaminase antibody (tTG IgA) testing as the
preferred and proficient single screening test for patients over 2 years old
[1]. Tricore Laboratories, utilized by the University of New Mexico, routinely
performs total serum IgA levels, anti-deamidated gliadin IgA antibody (AGA
IgA), and tissue transglutaminase IgA antibody (tTG) levels when a celiac
serology is requested. Though this combination of tests is performed to
increase the overall sensitivity of the screening, positive AGA in the setting
of negative tTG has often been considered a false positive result requiring
additional workup [1,2].
Of note, an additional immune-mediated enteropathy that often presents
with nonspecific symptomatology is Eosinophilic Esophagitis (EoE). EoE is a
chronic inflammatory process in which the esophageal epithelia is believed
to lose its barrier function ultimately resulting in esophageal inflammation,
most notably eosinophilic infiltration. Patients often present with signs and
symptoms of esophageal dysfunction, some of which may overlap many of
the presenting symptoms of celiac disease. To date, diagnosis relies on
clinical suspicion after ruling out other potential causes with ultimate
confirmation by biopsy [3].
The purpose of our evaluation is to understand the diagnostic implications of
negative tTG IgA in the setting of positive AGA IgA in pediatric patients who
are consuming gluten at the first evaluation. Through recent observation it
has been shown that this result pattern suggests that the likelihood of celiac
disease is in fact very low, though may be indicative of other conditions,
most consistently eosinophilic esophagitis. Therefore, in the presence of a
negative tTG, a positive anti-gliadin antibody should be considered a false
positive test for celiac disease, though still suggests notable enteropathy
such as EoE.

Cases

Discussion

Over the last 18 months, the UNM Division of Pediatric Gastroenterology
has identified 8 children with a positive AGA and negative tTG, all with an
initial presentation of persistent gastrointestinal distress and all while
continuing to consume gluten. The patients range in age from 2 to 17 years
old. Most are considered otherwise healthy, though few have notable
comorbidities including one with cystic fibrosis and another with notable
depression and anxiety. As noted in Table 1, 4 patients have undergone
diagnostic endoscopy with the other 4 currently pending endoscopy
scheduling. Of the 4 children status post endoscopy, 3 have confirmed
eosinophilic esophagitis per endoscopy with confirmatory histologic
evaluation (Image A-C) and 1 had overall normal endoscopic results, all
without evidence of celiac disease.
Table 1. Serologic and EGD Results for 8 Patients With GI Distress, Celiac Screening
Patient

tTG (Ref 0-14.9)

AGA (Ref 0-14.9)

EGD Results

A

<0.5

19.8

EoE

B

<0.5

239

EoE

C

<0.5

28.2

EoE

D

<0.5

>250

No inflammatory changes

E

5.9

47

pending

F

<0.5

21.4

pending

G

<0.5

153

pending

H

<0.5

24.8

pending

Many gastroenteropathies present with similar and overall nonspecific
symptoms, oftentimes requiring empiric treatment in conjunction with a wide
array of screening. Celiac serology is a common screening test performed for
this specific purpose. Though tTG positivity has long been considered the
standard for initial diagnosis of celiac disease, many laboratories have added
at least one additional serologic test to the celiac screen with the intention of
increasing screening sensitivity. The University of New Mexico relies on
Tricore Laboratories for the majority of the laboratory testing. Tricore’s celiac
screen includes baseline IgA levels, tTG IgA, and AGA IgA levels. It has often
been thought that negative tTG in the setting of positive AGA has been
representative of a false positive, which poses the question of the validity and
necessity of AGA testing in screening for celiac disease.
The results of this analysis suggest that, though negative tTG in conjunction
with positive AGA doesn’t necessarily point to celiac disease, this result
pattern may point to something else useful. Positive AGA in the presence of
negative tTG suggests that the likelihood of celiac disease is very low, though
may be indicative of other conditions such as eosinophilic esophagitis.
We recognize the limitations of this analysis given the small sample size,
though a more comprehensive 10-year retrospective study is planned.

Positive tTG is still believed to be the single best diagnostic test for celiac
disease alone. Common serologic screening often involves at least one
additional test that may include AGA as it does at Tricore Laboratories.
Based on the preliminary results of this ongoing analysis, the presence of a
negative tTG with a positive anti-gliadin antibody is likely representative of
false positivity for celiac disease, though has been consistently found with
eosinophilic esophagitis.
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Images A-C: Images A through C were obtained during EGD of patient B. Image A
and B are gross visual representations of the esophagus with evidence of eosinophilic
esophagitis including mucosal changes with white plaques and linear furrowing. Image
C is a histological sample obtained from the same EGD with pathology report noting
reactive squamous mucosa with increased eosinophilic infiltration also consistent with
eosinophilic esophagitis.
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